Drug Trial Radar · NCT00370331
RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag
Last checked: Nov 20, 2026Latest source record: Apr 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
197
Actual
Start
Nov 2006
Primary completion
Jul 2008
Study completion Jul 2008
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 31, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The rationale for this Phase III study is to evaluate the 6 month safety and efficacy of eltrombopag in the treatment of previously treated subjects with chronic ITP. The starting dose of eltrombopag, 50 mg, once daily was selected based upon the observed efficacy, safety and pharmacokinetics in a dose-finding Study (TRA100773). This Phase III study is a randomized, double-blind, placebo-controlled, Phase III study, to evaluate efficacy, safety and tolerability of eltrombopag, initially administered as 50 mg oral tablets once daily for six months in adult subjects with previously treated chronic ITP. Subjects will be randomized 2:1, eltrombopag to placebo, and will be stratified based upon splenectomy status, use of ITP medication at baseline and baseline platelet count less than or equal to 15,000/µL. Subjects will receive study medication for 6 months, during which the dose of study medication may be adjusted based upon individual platelet counts. In addition, subjects may taper off concomitant ITP medications and may receive any rescue treatments as dictated by local standard of care. After discontinuation of study medication, subjects will complete follow-up visits at weeks 1, 2, 4 and months 3 and 6.
Conditions
- Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopagDrug
Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
PlaceboDrug
Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of RespondersTime frame: Baseline; each on-therapy treatment day; Weeks 10, 14, 18, 22, and 26; and Weeks 1, 2, and 4 post-treatment
Locations
115 sites in 25 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Duarte, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Hollywood, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Savannah, Georgia
GSK Investigational Site
Honolulu, Hawaii
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Worcester, Massachusetts
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Buffalo, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Lawton, Oklahoma
GSK Investigational Site
Portland, Oregon
GSK Investigational Site
Willow Grove, Pennsylvania
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Lubbock, Texas
GSK Investigational Site
Lubbock, Texas
GSK Investigational Site
Arlington, Virginia
GSK Investigational Site
Seattle, Washington
GSK Investigational Site
Tacoma, Washington
GSK Investigational Site
Vienna, Austria
GSK Investigational Site
Burnaby, British Columbia, Canada
GSK Investigational Site
St. John's, Newfoundland and Labrador, Canada
GSK Investigational Site
Hamilton, Ontario, Canada
GSK Investigational Site
Weston, Ontario, Canada
GSK Investigational Site
Greenfield Park, Quebec, Canada
GSK Investigational Site
Laval, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Jiang Su Province, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Tianjin, China
GSK Investigational Site
Brno, Czechia
GSK Investigational Site
Hradec Králové, Czechia
Showing 40 of 115 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.